Comparative Pharmacology
Head-to-head clinical analysis: GILDAGIA versus STERI STAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GILDAGIA versus STERI STAT.
GILDAGIA vs STERI-STAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GILDAGIA (lixisenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It binds to and activates the GLP-1 receptor, increasing glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon secretion, slowing gastric emptying, and promoting satiety.
Binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis by blocking peptide bond formation and translocation.
20 mg orally once daily, with or without food.
Adults: 1 gram intravenously every 8 hours infused over 60 minutes.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in healthy volunteers, allowing once-daily dosing.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min).
Primarily hepatic metabolism; renal excretion of unchanged drug is minimal (<1%). Biliary/fecal excretion accounts for ~85% of the administered dose, with the remainder as metabolites in urine.
Renal excretion of unchanged drug accounts for approximately 95% of elimination; biliary/fecal elimination is minimal (<5%).
Category C
Category C
Corticosteroid
Corticosteroid